All In Biotech

NDA 050817 · Baxter Hlthcare

Cefepime In Plastic Container

Cefepime Hydrochloride · Injection

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Aug 5, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

78

22 Phase 3, 8 recruiting

FAERS reports

14,535

13,640 serious, 3,124 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 25, 2026.

Cefepime Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: pneumonia ( 1.1 ); empiric therapy for febrile neutropenic patients ( 1.2 ); uncomplicated and complicated urinary tract infections ( 1.3 ); uncomplicated skin and skin structure infections ( 1.4 ); and complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [ see Clinical Studies (14) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella...

Mechanism: Cefepime is an antibacterial drug. [See Microbiology (12.4) ]

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • CEFEPIME IN PLASTIC CONTAINER · CEFEPIME HYDROCHLORIDE EQ 2GM BASE/100ML (EQ 20MG BASE/ML) · INJECTABLE, INJECTION · Prescription
  • CEFEPIME IN PLASTIC CONTAINER · CEFEPIME HYDROCHLORIDE EQ 1GM BASE/50ML (EQ 20MG BASE/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefepime" as an intervention, any sponsor and status, largest first.

All 78 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,505
  • acute kidney injury1,185
  • off label use1,146
  • pyrexia919
  • febrile neutropenia696
  • pneumonia689
  • hypotension565
  • sepsis562
  • encephalopathy510
  • thrombocytopenia493
  • neutropenia486
  • septic shock472

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004109
2005113
2006142
2007130
2008190
2009279
2010204
2011244
2012287
2013267
2014392
2015557
2016587
2017809
2018924
2019896
20201,429
20211,292
20221,259
20231,087
20241,317
20251,184
2026837

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Oct 30, 2026

    Cefepime Hydrochloride in Plastic Container, Injection, 1g/50 mL (NDC 0338-1301-41). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Oct 30, 2026

    Cefepime Hydrochloride in Plastic Container, Injection, 2g/100mL (NDC 0338-1301-48). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 276 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.